HK Stock Market Move | CSPC PHARMA (01093) rises more than 3%. The II phase clinical trial of SYS 6026 injection for the treatment of HPV16 or 18-related HSIL has officially started in China.

CSPC PHARMA (01093) rose more than 3%, up 3.11% to HK$8.67 as of press time, with a turnover of HK$152 million. On the news front, CSPC PHARMA recently announced that the Phase II clinical trial of SYS 6026 injection developed by the group for the treatment of high-grade squamous intraepithelial lesions (HSIL) associated with human papillomavirus (HPV) types 16 or 18 has officially commenced in China. Previously, the group had received a clinical trial approval notification from the National Medical Products Administration of the People's Republic of China in November 2024 and subsequently initiated a Phase I clinical trial to evaluate the safety and tolerance of the product in patients with HPV16 or 18-related HSIL. The Phase II clinical trial now underway is a multicenter, randomized, double-blind, placebo-controlled clinical study aimed at evaluating the effectiveness and safety of the product compared to placebo in treating participants with HPV16 or 18-related HSIL. Recruitment and screening of participants for the project are currently actively underway.